April 12, 2021
FDA: Class I recall of Medtronic’s Valiant Navion Thoracic Stent Graft System
Editor's Note
The Food & Drug Administration (FDA), on April 9, identified the recall of Medtronic’s Valiant Navion Thoracic Stent Graft System as Class I, the most serious.
The recall was initiated because of the risk of stent fractures and endoleak concerns. The system is used to repair lesions of the descending thoracic aorta.
There have been 11 reported issues, including two injuries and one death. Distribution dates were November 12, 2018 to February 10, 2021.
Read More >>
Free Daily News
- CDC communication breakdown raises public health risk
- Study: Shorter radiation schedule matches safety of standard prostate cancer treatment
- Poll: Healthcare cybersecurity leaders overlook AI-enabled physical security gaps
- ASC improves hospital efficiency, maintains outcomes despite higher-acuity joint replacement patients
- Hospital support staff cuts raise risk of infection, delays in care
- Study: Blocking stress-linked prolactin surge relieves postoperative pain in women
- Report ranks states by nursing opportunity
- Report: Hospitals double down on ASCs as outpatient shift accelerates
- Centralized waitlists slash joint replacement wait times in Canada, study shows
- Airborne bacteria pose hidden threat in cardiac ORs, study warns
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement